Research Analysts’ Recent Ratings Updates for Jazz Pharmaceuticals (JAZZ)

Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

• 5/22/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $232.00 to $301.00. They now have an “overweight” rating on the stock.
• 5/21/2026 – Jazz Pharmaceuticals is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $229.00 price target on the stock.
• 5/21/2026 – Jazz Pharmaceuticals was upgraded by Sanford C. Bernstein to “hold”.
• 5/19/2026 – Jazz Pharmaceuticals was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $307.00 price target on the stock, up from $188.00.
• 5/7/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $245.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $239.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $220.00 to $275.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals was given a new $252.00 price target by Robert W. Baird.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $225.00 to $234.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $195.00 to $258.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $250.00 to $265.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Jazz Pharmaceuticals had its price target raised by Leerink Partners from $215.00 to $225.00. They now have an “outperform” rating on the stock.
• 4/20/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $224.00 to $225.00. They now have an “overweight” rating on the stock.
• 4/10/2026 – Jazz Pharmaceuticals is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $227.00 price target on the stock.
• 4/9/2026 – Jazz Pharmaceuticals was upgraded by Raymond James Financial, Inc. to “moderate buy”.
• 3/27/2026 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 1,287 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,191,305.28. The trade was a 16.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the sale, the director owned 7,024 shares in the company, valued at $1,348,608. The trade was a 32.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 74,015 shares of company stock valued at $14,180,486 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.